Aptose Biosciences Inc (TSE:APS) (NASDAQ:APTO)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Thursday.

Aptose Biosciences (APS) opened at 1.83 on Thursday. Aptose Biosciences has a 1-year low of $1.05 and a 1-year high of $4.02. The firm’s 50-day moving average price is $1.85 and its 200 day moving average price is $1.58. The firm’s market capitalization is $43.97 million.

TRADEMARK VIOLATION NOTICE: “HC Wainwright Reaffirms Buy Rating for Aptose Biosciences Inc (APS)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/09/hc-wainwright-reaffirms-buy-rating-for-aptose-biosciences-inc-aps.html.

In related news, Director Warren Whitehead bought 17,000 shares of the business’s stock in a transaction dated Tuesday, June 27th. The stock was purchased at an average cost of C$1.51 per share, for a total transaction of C$25,670.00. Insiders purchased a total of 72,000 shares of company stock valued at $101,920 over the last 90 days.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Receive News & Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.